 BRYAN, Texas, May 06, 2021 GLOBE NEWSWIRE -- iBio, Inc. NYSEA:IBIO iBio or the Company, a biotech innovator and biologics contract manufacturing organization, today provided an update on its IBIO-201 program and reported on its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. 